 | Up a level |
Pal, Sumanta K., Rosenberg, Jonathan E., Hoffman-Censits, Jean H., Berger, Raanan, Quinn, David I., Galsky, Matthew D., Wolf, Juergen, Dittrich, Christian, Keam, Bhumsuk, Delord, Jean-Pierre, Schellens, Jan H. M., Gravis, Gwenaelle, Medioni, Jacques, Maroto, Pablo, Sriuranpong, Virote, Charoentum, Chaiyut, Burris, Howard A., Grunwald, Viktor, Petrylak, Daniel, Vaishampayan, Ulka 
ORCID: 0000-0001-5800-4571, Gez, Eliahu, De Giorgi, Ugo, Lee, Jae-Lyun, Voortman, Jens, Gupta, Sumati, Sharma, Sunil, Mortazavi, Amir, Vaughn, David J., Isaacs, Randi, Parker, Katie, Chen, Xueying, Yu, Kun, Porter, Dale, Porta, Diana Graus and Bajorin, Dean F.
(2018).
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Cancer Discov., 8 (7).
S. 812 - 822.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 2159-8290
Pal, Sumanta K., Rosenberg, Jonathan E., Keam, Bhumsuk, Wolf, Juergen, Berger, Raanan, Dittrich, Christian, Hoffman-Censits, Jean H., Quinn, David ORCID: 0000-0002-1411-0417, van der Noll, Ruud, Burris, Howard A., Galsky, Matt D., Gravis, Gwenaelle, Lee, Jae-Lyun, Medioni, Jacques, Mortazavi, Amir, Maroto, Pablo, Parker, Katie, Chen, Xueying, Isaacs, Randi and Bajorin, Dean F.
(2016).
Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755